NCT06809426View on ClinicalTrials.gov

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

October 14, 2024

Study Completion Date

October 24, 2024

Conditions
PSMA PET-Positive Castration-Resistant Prostate Cancer
Interventions
DRUG

177Lu-LNC1011

75 mCi (2.78 GBq) of 177Lu-LNC1011 Injection intravenously each time, injections every 6 weeks, not to exceed a total of 6 injections.

Trial Locations (1)

214000

Affiated Hospital of Jiangnan University, Wuxi

All Listed Sponsors
lead

Affiliated Hospital of Jiangnan University

OTHER

NCT06809426 - Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter